ME02749B - Deuterisani derivati ivakaftora - Google Patents
Deuterisani derivati ivakaftoraInfo
- Publication number
- ME02749B ME02749B MEP-2017-112A MEP2017112A ME02749B ME 02749 B ME02749 B ME 02749B ME P2017112 A MEP2017112 A ME P2017112A ME 02749 B ME02749 B ME 02749B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- compound according
- pharmaceutically acceptable
- labeled
- deuterium
- Prior art date
Links
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical class C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 229910052805 deuterium Inorganic materials 0.000 claims 7
- 230000000155 isotopic effect Effects 0.000 claims 5
- 150000001975 deuterium Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (18)
1.Jedinjenje formule I:ili njegova farmaceutski prihvatljiva so, gdesvaki od X1, X2, X3, X4, X5, X6, i X7 je nezavisno vodonik ili deuterijum;Y1, Y2, i Y3 su CD3;svaki od Y4, Y5, i Y6 je nezavisno CH3 ili CD3; gde faktor izotopskog obogaćenja za svaki obeleženi atum deuterijuma je bar 3500; i gde bilo koji atom koji nije obeležen kao deuterijum je prisutan u svojoj prirodnoj izotopskoj rasprostranjenosti, uz uslov da jedinjenje formule I nije jedinjenje 100:Jedinjenje 100
2.Jedinjenje prema zahtevu 1, gde su X1, X2, X3i X4 isti.
3.Jedinjenje prema zahtevu 2, gde su X4, X5i X6 isti.
4.Jedinjenje prema zahtevu 2 ili zahtevu 3, gde su X6 i X7 isti.
5.Jedinjenje prema bilo kom od prethodnih zahteva, gde je X5 deuterijum.
6.Jedinjenje prema bilo kom od prethodnih zahteva, gde su X4, X5i X6 CD3.
7.Jedinjenje prema bilo kom od zahteva 1 do 4, gde je X5 vodonik.
8.Jedinjenje prema bilo kom od zahteva 1 do 4, gde su X4, X5 i X6 CH3.
9.Jedinjenje prema zahtevu 1, gde je faktor izotopskog obogaćenja za svaki obeleženi atom deuterijuma bar 6000.
10.Jedinjenje prema zahtevu 1, gde je faktor izotopskog obogaćenja za svaki obeleženi atom deuterijuma bar 6333,3.
11.Jedinjenje prema zahtevu 1, gde je faktor izotopskog obogaćenja za svaki obeleženi atom deuterijuma bar 6466,7.
12.Jedinjenje prema zahtevu 1 ili prema bilo kom od zahteva 9 do 11, gde je jedinjenje formule I bilo koje jedinjenje iz donje tabele, Jed.# X1 X2 X3 X4 X5 X6 X7 Y1 Y2 Y3 Y4 Y5 Y6 101 H H H H D H H CD3 CD3 CD3 CD3 CD3 CD3 102 H H H H D H H CD3 CD3 CD3 CH3 CH3 CH3 105 H H H H H H H CD3 CD3 CD3 CD3 CD3 CD3 106 H H H H H H H CD3 CD3 CD3 CH3 CH3 CH3 ili njegova farmaceutski prihvatljiva so.
13.Jedinjenje prema zahtevu 1 ili prema bilo kom od zahteva 9 do 11, gde je jedinjenje formule I jedinjenje iz donje tabele, Jed.# X1 X2 X3 X4 X5 X6 X7 Y1 Y2 Y3 Y4 Y5 Y6 106 H H H H H H H CD3 CD3 CD3 CH3 CH3 CH3 ili njegova farmaceutski prihvatljiva so.
14.Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od prethodnih zahteva ili njegovu farmaceutski prihvatljivu so; i farmaceutski prihvatljiv nosač.
15.Jedinjenje prema bilo kom od zahteva 1-13 ili kompozicija prema zahtevu 14 za upotrebu u lečenju cistične fibroze.
16.Upotreba jedinjenja prema bilo kom od zahteva 1-13 ili kompozicije prema zahtevu 14 u proizvodnji leka za cističnu fibrozu.
17.Jedinjenje prema bilo kom od zahteva 1-13 ili kompozicije prema zahtevu 14 za upotrebu u lečenju hronične opstruktivne bolesti pluća (HOBP).
18. Upotreba jedinjenja prema bilo kom od zahteva 1-13, ili kompozicije prema zahtevu 14, u proizvodnji leka za hroničnu opstruktivnu bolest pluća (HOBP).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487497P | 2011-05-18 | 2011-05-18 | |
| PCT/US2012/038297 WO2012158885A1 (en) | 2011-05-18 | 2012-05-17 | Deuterated derivatives of ivacaftor |
| EP12725197.3A EP2709986B1 (en) | 2011-05-18 | 2012-05-17 | Deuterated derivatives of ivacaftor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02749B true ME02749B (me) | 2018-01-20 |
Family
ID=46201810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-325A ME03652B (me) | 2011-05-18 | 2012-05-17 | Deuterisani derivati ivakaftora |
| MEP-2017-112A ME02749B (me) | 2011-05-18 | 2012-05-17 | Deuterisani derivati ivakaftora |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-325A ME03652B (me) | 2011-05-18 | 2012-05-17 | Deuterisani derivati ivakaftora |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP3235812B1 (me) |
| JP (2) | JP6063455B2 (me) |
| AU (5) | AU2012255711B2 (me) |
| BR (1) | BR112013029240B1 (me) |
| CA (1) | CA2834574C (me) |
| CY (2) | CY1119090T1 (me) |
| DK (2) | DK2709986T3 (me) |
| EA (1) | EA028378B1 (me) |
| ES (2) | ES2628465T3 (me) |
| HR (2) | HRP20170754T1 (me) |
| HU (1) | HUE032771T2 (me) |
| LT (1) | LT2709986T (me) |
| ME (2) | ME03652B (me) |
| MX (1) | MX349159B (me) |
| PL (2) | PL2709986T3 (me) |
| PT (2) | PT3235812T (me) |
| RS (2) | RS59744B1 (me) |
| SI (2) | SI2709986T1 (me) |
| SM (2) | SMT201900679T1 (me) |
| WO (1) | WO2012158885A1 (me) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| PL2709986T3 (pl) * | 2011-05-18 | 2017-09-29 | Concert Pharmaceuticals Inc. | Deuterowane pochodne iwakaftoru |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| CN104619321A (zh) * | 2012-04-06 | 2015-05-13 | Uab研究基金会 | 用于增加cftr活性的方法 |
| JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| WO2014078842A1 (en) * | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
| EP3798214B1 (en) | 2014-10-06 | 2022-09-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
| US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
| US20180353500A1 (en) * | 2015-09-21 | 2018-12-13 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated cftr potentiators |
| MA42954A (fr) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals Europe Ltd | Potentialisateurs cftr deutérés |
| BR112018070747B1 (pt) * | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
| EP3472156B1 (en) | 2016-06-21 | 2023-06-07 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| MA49235B1 (fr) | 2016-12-09 | 2021-02-26 | Vertex Pharma | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| JP2017105824A (ja) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| SG11202004264VA (en) * | 2017-12-01 | 2020-06-29 | Vertex Pharma | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| JP6654223B2 (ja) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド | 重水素化されたｃｆｔｒ増強物質 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| MX2022001827A (es) | 2019-08-14 | 2022-06-09 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica. |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| LV15575A (lv) | 2019-12-20 | 2021-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CA3188787A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
| EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076618A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CR20230198A (es) | 2020-10-07 | 2023-07-03 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN116670143A (zh) | 2020-10-07 | 2023-08-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| TW202233635A (zh) | 2020-10-07 | 2022-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| JP2025506382A (ja) | 2022-02-03 | 2025-03-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
| KR20240155228A (ko) | 2022-02-03 | 2024-10-28 | 버텍스 파마슈티칼스 인코포레이티드 | (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법 |
| AU2023218262A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20250008540A (ko) | 2022-04-06 | 2025-01-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| US20250340568A1 (en) | 2022-05-16 | 2025-11-06 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
| CA3253026A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | TREATMENT METHODS FOR CYSTIC FIBROSIS |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025166342A1 (en) | 2024-02-04 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis |
| EP4648753B1 (en) | 2024-02-07 | 2026-02-18 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| BR0209325A (pt) | 2001-05-03 | 2004-07-20 | Hoffmann La Roche | Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| MX341797B (es) * | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| BRPI0516170A (pt) | 2004-09-29 | 2008-08-26 | Cordis Corp | formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina |
| EP1974212A1 (en) | 2005-12-27 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| ES2377840T3 (es) | 2006-05-12 | 2012-04-02 | Vertex Pharmaceuticals, Inc. | Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida |
| AU2008299921B2 (en) * | 2007-09-13 | 2012-03-01 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| LT3345625T (lt) | 2008-08-13 | 2021-02-10 | Vertex Pharmaceuticals Incorporated | Farmacinė kompozicija ir jos vartojimas |
| WO2010028015A2 (en) * | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| PL2709986T3 (pl) * | 2011-05-18 | 2017-09-29 | Concert Pharmaceuticals Inc. | Deuterowane pochodne iwakaftoru |
-
2012
- 2012-05-17 PL PL12725197T patent/PL2709986T3/pl unknown
- 2012-05-17 HR HRP20170754TT patent/HRP20170754T1/hr unknown
- 2012-05-17 DK DK12725197.3T patent/DK2709986T3/en active
- 2012-05-17 AU AU2012255711A patent/AU2012255711B2/en active Active
- 2012-05-17 SM SM20190679T patent/SMT201900679T1/it unknown
- 2012-05-17 MX MX2013013450A patent/MX349159B/es active IP Right Grant
- 2012-05-17 PT PT171603863T patent/PT3235812T/pt unknown
- 2012-05-17 BR BR112013029240-7A patent/BR112013029240B1/pt active IP Right Grant
- 2012-05-17 SM SM20170302T patent/SMT201700302T1/it unknown
- 2012-05-17 PL PL17160386T patent/PL3235812T3/pl unknown
- 2012-05-17 WO PCT/US2012/038297 patent/WO2012158885A1/en not_active Ceased
- 2012-05-17 ES ES12725197.3T patent/ES2628465T3/es active Active
- 2012-05-17 ES ES17160386T patent/ES2758028T3/es active Active
- 2012-05-17 LT LTEP12725197.3T patent/LT2709986T/lt unknown
- 2012-05-17 ME MEP-2019-325A patent/ME03652B/me unknown
- 2012-05-17 HU HUE12725197A patent/HUE032771T2/en unknown
- 2012-05-17 JP JP2014511524A patent/JP6063455B2/ja active Active
- 2012-05-17 EP EP17160386.3A patent/EP3235812B1/en active Active
- 2012-05-17 RS RS20191494A patent/RS59744B1/sr unknown
- 2012-05-17 DK DK17160386T patent/DK3235812T3/da active
- 2012-05-17 RS RS20170601A patent/RS56096B1/sr unknown
- 2012-05-17 PT PT127251973T patent/PT2709986T/pt unknown
- 2012-05-17 EP EP12725197.3A patent/EP2709986B1/en active Active
- 2012-05-17 SI SI201230988A patent/SI2709986T1/sl unknown
- 2012-05-17 EA EA201391615A patent/EA028378B1/ru unknown
- 2012-05-17 CA CA2834574A patent/CA2834574C/en active Active
- 2012-05-17 ME MEP-2017-112A patent/ME02749B/me unknown
- 2012-05-17 SI SI201231694T patent/SI3235812T1/sl unknown
-
2016
- 2016-12-16 JP JP2016243941A patent/JP2017078082A/ja active Pending
-
2017
- 2017-06-02 CY CY20171100584T patent/CY1119090T1/el unknown
- 2017-07-27 AU AU2017208313A patent/AU2017208313A1/en not_active Abandoned
-
2019
- 2019-08-28 AU AU2019222862A patent/AU2019222862B2/en active Active
- 2019-11-25 HR HRP20192114TT patent/HRP20192114T1/hr unknown
- 2019-12-04 CY CY20191101275T patent/CY1122498T1/el unknown
-
2021
- 2021-02-15 AU AU2021200970A patent/AU2021200970B2/en active Active
- 2021-06-08 AU AU2021203786A patent/AU2021203786B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02749B (me) | Deuterisani derivati ivakaftora | |
| PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
| NZ616637A (en) | Preparation of high-purity gadobutrol | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| PH12014502524A1 (en) | Carboxylic acid compounds | |
| JP2012515720A5 (me) | ||
| HRP20250776T1 (hr) | Elafibranor za uporabu u liječenju primarnog bilijarnog kolangitisa | |
| BR112014001801A2 (pt) | indazóis | |
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| TW200740789A (en) | Pyridine and pyrimidine derivatives as mGluR2 antagonists | |
| AR062104A1 (es) | Derivados de quinuclidina como antagonistas de m3 | |
| HRP20150797T1 (hr) | Supstituirani derivati ksantina | |
| HRP20160048T1 (hr) | Stabilizacija vitamina b12 | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| EA201591957A1 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| PE20141048A1 (es) | Combinacion que comprende umeclidinio y un corticosteroide | |
| ZA201401568B (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
| RU2012151400A (ru) | ПРИМЕНЕНИЕ 5α-АНДРОСТАН (АЛКИЛ)-3β,5,6β-ТРИОЛА ДЛЯ ИЗГОТОВЛЕНИЯ НЕЙРОПРОТЕКТОРНЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| HRP20191348T1 (hr) | Aminosteroidi za liječenje bolesti povezanih s ptp1b | |
| JP2013533867A5 (me) | ||
| GEP20156386B (en) | New crystal form vii of agomelatine, preparation method and usage thereof, and pharmaceutical compositions containing thereof | |
| SG195210A1 (en) | Hyperforin analogs, methods of synthesis, and uses thereof | |
| WO2014006636A3 (en) | Stable compositions of fesoterodine | |
| UA108277C2 (ru) | Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения | |
| EA029678B9 (ru) | Четвертичные соли пиперидиния |